Carlos Gómez-Martín
About
Carlos Gómez-Martín is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Carlos Gómez-Martín has authored 46 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 9 papers in Molecular Biology. Recurrent topics in Carlos Gómez-Martín's work include Gastric Cancer Management and Outcomes (14 papers), Colorectal Cancer Treatments and Studies (9 papers) and HER2/EGFR in Cancer Research (8 papers). Carlos Gómez-Martín is often cited by papers focused on Gastric Cancer Management and Outcomes (14 papers), Colorectal Cancer Treatments and Studies (9 papers) and HER2/EGFR in Cancer Research (8 papers). Carlos Gómez-Martín collaborates with scholars based in Spain, United States and South Korea. Carlos Gómez-Martín's co-authors include Elena Garralda, Bruno Sangro, Mercedes Iñarrairaegui, José Ignacio Riezu‐Boj, Manuel de la Mata, Juan José Lasarte, Carlos Alfaro, Ignacio Melero, Pablo Sarobe and José Luis Perez‐Gracia and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Hepatology and Annals of Oncology.
In The Last Decade
Carlos Gómez-Martín
43 papers receiving 1.5k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Carlos Gómez-Martín Spain | 15 | 906 | 645 | 406 | 321 | 274 | 46 | 1.6k | ||
| Jaekyung Cheon South Korea | 22 | 720 0.8× | 477 0.7× | 365 0.9× | 198 0.6× | 166 0.6× | 92 | 1.4k | ||
| Chiara Caparello Italy | 15 | 569 0.6× | 291 0.5× | 305 0.8× | 98 0.3× | 325 1.2× | 45 | 1.2k | ||
| Jean‐Christophe Weber France | 22 | 901 1.0× | 815 1.3× | 326 0.8× | 163 0.5× | 94 0.3× | 60 | 1.7k | ||
| Tongyu Lin China | 17 | 484 0.5× | 230 0.4× | 139 0.3× | 168 0.5× | 216 0.8× | 71 | 1.1k | ||
| Wei‐Chen Lee Taiwan | 20 | 433 0.5× | 1.0k 1.6× | 186 0.5× | 150 0.5× | 215 0.8× | 63 | 1.5k | ||
| William A. Kokal United States | 17 | 657 0.7× | 304 0.5× | 263 0.6× | 183 0.6× | 352 1.3× | 25 | 1.5k | ||
| Stéphane Cattan France | 18 | 355 0.4× | 729 1.1× | 211 0.5× | 184 0.6× | 278 1.0× | 36 | 2.3k | ||
| Sameh Mikhail United States | 22 | 747 0.8× | 229 0.4× | 415 1.0× | 103 0.3× | 270 1.0× | 70 | 1.5k | ||
| Eléonora De Martin France | 14 | 605 0.7× | 400 0.6× | 166 0.4× | 141 0.4× | 126 0.5× | 47 | 1.1k | ||
| Michael Doukas Netherlands | 18 | 414 0.5× | 174 0.3× | 301 0.7× | 105 0.3× | 174 0.6× | 66 | 1.1k |
Countries citing papers authored by Carlos Gómez-Martín
Since
Specialization
Citations
This map shows the geographic impact of Carlos Gómez-Martín's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carlos Gómez-Martín with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carlos Gómez-Martín more than expected).
Fields of papers citing papers by Carlos Gómez-Martín
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Carlos Gómez-Martín. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carlos Gómez-Martín. The network helps show where Carlos Gómez-Martín may publish in the future.
Co-authorship network of co-authors of Carlos Gómez-Martín
This figure shows the co-authorship network connecting the top 25 collaborators of Carlos Gómez-Martín. A scholar is included among the top collaborators of Carlos Gómez-Martín based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carlos Gómez-Martín. Carlos Gómez-Martín is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Matilla, Ana, Marı́a Varela, Mercedes Iñarrairaegui, et al.. (2025). Health-related quality of life in patients with unresectable hepatocellular carcinoma treated with SIRT and nivolumab: a sub-analysis of the NASIR-HCC trial. Journal of Patient-Reported Outcomes. 9(1). 39–39.
2.
Alsina, María, Míriam Cuatrecasas, María Jesús Fernández‐Aceñero, et al.. (2025). Biomarkers in gastroesophageal cancer 2025: an updated consensus statement by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clinical & Translational Oncology. 27(9). 3580–3594.
3.
López, Carlos, Mariona Calvo, Juan Carlos Cámara, et al.. (2024). SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023). Clinical & Translational Oncology. 26(11). 2800–2811.
4.
Paredes, D., et al.. (2023). Reactivación de citomegalovirus en pacientes con gastritis inmunomediada. Enfermedades infecciosas y microbiologia clinica (English ed ). 41(5). 298–300.
5.
Smyth, Elizabeth, M. Mauer, Chiara Alessandra Cella, et al.. (2023). O-6 EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients (pts) with resected gastroesophageal adenocarcinoma (GEA) following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—an open-label randomized controlled phase II study. Annals of Oncology. 34. S182–S183.
6.
Matilla, Ana, Marı́a Varela, Mercedes Iñarrairaegui, et al.. (2022). Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study. Journal for ImmunoTherapy of Cancer. 10(11). e005457–e005457.
7.
Montés, Ana Fernández, Julia Alcaide, María Alsina, et al.. (2022). SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clinical & Translational Oncology. 24(4). 658–669.
8.
Sangro, Bruno, Kazushi Numata, Yi‐Hsiang Huang, et al.. (2021). P-61 Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073. Annals of Oncology. 32. S117–S117.
9.
Paredes, D., Covadonga Gómez‐Cuervo, Carlos Gómez-Martín, et al.. (2021). Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid. Journal of Thrombosis and Thrombolysis. 53(2). 471–478.
10.
Yarza, Ramón, D. Paredes, Flora López-López, et al.. (2020). SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death. European Journal of Cancer. 135. 242–250.
11.
López‐Ríos, Fernando, Carolina Domínguez, Paula Jiménez Fonseca, et al.. (2016). PI3K upregulation as a negative predictive factor of survival in HER2 amplified gastric cancer treated with Trastuzumab.. Journal of Clinical Oncology. 34(15_suppl). e15567–e15567.
12.
Gómez-Martín, Carlos, Fernando López‐Ríos, Jorge Aparicio, et al.. (2014). A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond. Cancer Letters. 351(1). 30–40.
13.
Finn, Richard S., Ronnie T.P. Poon, Thomas Yau, et al.. (2013). Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma. Journal of Hepatology. 59(6). 1271–1277.
14.
Boni, Valentina, Elena Garralda, Antonio Cubillo, et al.. (2013). Phase I clinical trials attrition related to central molecular prescreening.. Journal of Clinical Oncology. 31(15_suppl). 2600–2600.
15.
Gómez-Martín, Carlos, Antonio Irigoyen López, Raquel Serrano, et al.. (2012). Incidence of hand–foot syndrome with capecitabine in combination with chemotherapy as first-line treatment in patients with advanced and/or metastatic gastric cancer suitable for treatment with a fluoropyrimidine-based regimen. Clinical & Translational Oncology. 14(9). 689–697.
16.
García-García, Elena, Carlos Gómez-Martín, Bárbara Angulo, et al.. (2011). Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. Histopathology. 59(1). 8–17.
17.
Gómez-Martín, Carlos, Javier Bustamante, J.F. Castroagudı́n, et al.. (2011). Efficacy and Safety of Sorafenib in Combination With Mammalian Target of Rapamycin Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation. Liver Transplantation. 18(1). 45–52.
18.
Gómez-Martín, Carlos, et al.. (2010). Biliary cystadenocarcinoma with mesenchymal stroma. Clinical & Translational Oncology. 12(3). 234–237.
19.
Perez‐Gracia, José Luis, Rámón Colomer, Ana Ruiz‐Casado, et al.. (2001). High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial. Bone Marrow Transplantation. 27(2). 117–123.
20.
Castellano, Daniel, et al.. (1997). 100 Phase II study of gemcitabine and cisplatin every 3 weeks in patients with non-small cell lung cancer. Lung Cancer. 18. 28–29.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jaekyung Cheon Breakdown of academic impact, for papers by Chiara Caparello Breakdown of academic impact, for papers by Jean‐Christophe Weber Breakdown of academic impact, for papers by Tongyu Lin Breakdown of academic impact, for papers by Wei‐Chen Lee Breakdown of academic impact, for papers by William A. Kokal Breakdown of academic impact, for papers by Stéphane Cattan Breakdown of academic impact, for papers by Sameh Mikhail Breakdown of academic impact, for papers by Eléonora De Martin Breakdown of academic impact, for papers by Michael Doukas